Placebo-controlled study in neuromyelitis optica--Ethical and design considerations

Conclusion:
The approach we took in the design of the N-MOmentum trial might serve as a roadmap for other rare severe diseases when there is no proven therapy and no established clinical development path.

Source: Multiple Sclerosis - June 1, 2016 Category: Neurology Authors: Cree, B. A., Bennett, J. L., Sheehan, M., Cohen, J., Hartung, H.-P., Aktas, O., Kim, H. J., Paul, F., Pittock, S., Weinshenker, B., Wingerchuk, D., Fujihara, K., Cutter, G., Patra, K., Flor, A., Barron, G., Madani, S., Ratchford, J. N., Katz, E. Tags: Future Perspectives Source Type: research